ArticleAlimentary pharmacology & therapeutics2026
Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Editorial: Liver and Non-Liver Outcomes Between Different Subtypes of Steatotic Liver Disease.Alimentary pharmacology & therapeutics · 2026Article
- MetALD Molecular Signatures: What We Know, What We Lack, and How to Move Forward Through Integrated Multi-Omics.Metabolites · 2026Review
- Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe natural history of steatotic liver disease (SLD)-including major adverse liver outcomes (MALO), major adverse cardiovascular events (MACE), and all-cause mortality-remains inadequately defined in population-based settings.
aimsWe sought to quantify their incidence and compare risks across SLD subtypes.
methodsWe evaluated 244,760 UK Biobank participants, assessing metabolic dysfunction-associated SLD (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), or alcohol-associated liver disease (ALD), and examined outcomes across these subtypes.
resultsAmong the cohort, 47,949 (19.6%) had MASLD, 23,000 (9.4%) had MetALD, and 8085 (3.3%) had ALD. Of the 79,034 individuals with SLD (mean age 57.2; 72.4% female; 98.0% White), the incidence rates of MALO (per 1,000 person-years) were 1.91 for MASLD, 2.35 for MetALD, and 5.80 for ALD during a median follow-up of 13.5 years. Corresponding rates for MACE were 14.88, 15.48, and 19.36, and for all-cause mortality were 12.99, 13.59, and 20.93. After adjustment, ALD (hazard ratio [HR], 2.95; 95% CI, 2.64-3.29) and MetALD (HR, 1.23; 95% CI, 1.11-1.36) were associated with higher MALO risk than MASLD. ALD also showed higher risks of MACE and mortality than MetALD (MACE: HR, 1.17; 95% CI, 1.10-1.24; mortality: HR, 1.49; 95% CI, 1.41-1.58) or MASLD (MACE: HR, 1.17; 95% CI, 1.11-1.24; mortality: HR, 1.52; 95% CI, 1.44-1.60), whereas MetALD and MASLD showed no differences.
conclusionsIn the United Kingdom, ALD exhibited the highest liver, cardiovascular, and mortality risks, while MASLD and MetALD had similar cardiovascular and survival profiles but differed in liver-related risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.